Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Assessment of TANK-binding kinase 1 as a therapeutic target in cancer.

Literature DB >> 29218456

Assessment of TANK-binding kinase 1 as a therapeutic target in cancer.

Abstract

TANK-binding kinase 1 (TBK1) is central to multiple biological processes that promote tumorigenesis including cell division, autophagy, innate immune response and AKT-pro survival signaling. TBK1 is well studied and most known for its function in innate immunity. However, the serine threonine protein kinase received significant attention as a synthetic lethal partner and effector of the major oncogene, RAS. This review summarizes newly identified cancer promoting functions of TBK1 and evaluates the therapeutic potential of targeting TBK1 in cancer.

Entities: Disease Gene

Keywords: Autophagy; Cancer therapeutic target; Pancreatic cancer; RAS; TBK1

Year: 2017 PMID： 29218456 PMCID： PMC5842199 DOI： 10.1007/s12079-017-0438-y

Source DB: PubMed Journal: J Cell Commun Signal ISSN： 1873-9601 Impact factor: 5.782

33 in total

1. Activation of STAT6 by STING is critical for antiviral innate immunity.

Authors: Huihui Chen; Hui Sun; Fuping You; Wenxiang Sun; Xiang Zhou; Lu Chen; Jing Yang; Yutao Wang; Hong Tang; Yukun Guan; Weiwei Xia; Jun Gu; Hiroki Ishikawa; Delia Gutman; Glen Barber; Zhihai Qin; Zhengfan Jiang
Journal: Cell Date: 2011-10-14 Impact factor: 41.582

2. Molecular mechanisms of selective autophagy.

Authors: G M Fimia; G Kroemer; M Piacentini
Journal: Cell Death Differ Date: 2013-01 Impact factor: 15.828

3. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth.

Authors: Philipp Wild; Hesso Farhan; David G McEwan; Sebastian Wagner; Vladimir V Rogov; Nathan R Brady; Benjamin Richter; Jelena Korac; Oliver Waidmann; Chunaram Choudhary; Volker Dötsch; Dirk Bumann; Ivan Dikic
Journal: Science Date: 2011-05-26 Impact factor: 47.728

Review 4. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer.

Authors: Ilya Gukovsky; Ning Li; Jelena Todoric; Anna Gukovskaya; Michael Karin
Journal: Gastroenterology Date: 2013-06 Impact factor: 22.682

5. Mice lacking Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality.

Authors: Erica Marchlik; Paresh Thakker; Thaddeus Carlson; Zhaozhao Jiang; Mark Ryan; Suzana Marusic; Nadege Goutagny; Wen Kuang; G Roger Askew; Victoria Roberts; Stephen Benoit; Tianhui Zhou; Vincent Ling; Richard Pfeifer; Nancy Stedman; Katherine A Fitzgerald; Lih-Ling Lin; J Perry Hall
Journal: J Leukoc Biol Date: 2010-07-22 Impact factor: 4.962

6. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.

Authors: Yi-Hung Ou; Michael Torres; Rosalyn Ram; Etienne Formstecher; Christina Roland; Tzuling Cheng; Rolf Brekken; Ryan Wurz; Andrew Tasker; Tony Polverino; Seng-Lai Tan; Michael A White
Journal: Mol Cell Date: 2011-02-18 Impact factor: 17.970

7. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation.

Authors: Manohar Pilli; John Arko-Mensah; Marisa Ponpuak; Esteban Roberts; Sharon Master; Michael A Mandell; Nicolas Dupont; Wojciech Ornatowski; Shanya Jiang; Steven B Bradfute; Jack-Ansgar Bruun; Tom Egil Hansen; Terje Johansen; Vojo Deretic
Journal: Immunity Date: 2012-08-24 Impact factor: 31.745

8. The protein kinase IKKepsilon regulates energy balance in obese mice.

Authors: Shian-Huey Chiang; Merlijn Bazuine; Carey N Lumeng; Lynn M Geletka; Jonathan Mowers; Nicole M White; Jing-Tyan Ma; Jie Zhou; Nathan Qi; Dan Westcott; Jennifer B Delproposto; Timothy S Blackwell; Fiona E Yull; Alan R Saltiel
Journal: Cell Date: 2009-09-04 Impact factor: 41.582

9. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors: David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal: Nature Date: 2009-10-21 Impact factor: 49.962

10. p53 status determines the role of autophagy in pancreatic tumour development.

Authors: Mathias T Rosenfeldt; Jim O'Prey; Jennifer P Morton; Colin Nixon; Gillian MacKay; Agata Mrowinska; Amy Au; Taranjit Singh Rai; Liang Zheng; Rachel Ridgway; Peter D Adams; Kurt I Anderson; Eyal Gottlieb; Owen J Sansom; Kevin M Ryan
Journal: Nature Date: 2013-12-04 Impact factor: 49.962

14 in total

1. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.

Authors: Victoria H Cruz; Emily N Arner; Wenting Du; Alberto E Bremauntz; Rolf A Brekken
Journal: JCI Insight Date: 2019-04-02

2. Zika virus NS5 protein antagonizes type I interferon production via blocking TBK1 activation.

Authors: Shaoli Lin; Shixing Yang; Jia He; Johnathan D Guest; Zexu Ma; Liping Yang; Brian G Pierce; Qiyi Tang; Yan-Jin Zhang
Journal: Virology Date: 2018-12-06 Impact factor: 3.616

3. The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.

Authors: Hua Yang; Shengyan Xiang; Aslamuzzaman Kazi; Said M Sebti
Journal: J Biol Chem Date: 2020-01-30 Impact factor: 5.157

4. Autophagic flux is essential for the downregulation of D-dopachrome tautomerase by atractylenolide I to ameliorate intestinal adenoma formation.

Authors: Lu Li; Linlin Jing; Junjiang Wang; Wenjuan Xu; Xianling Gong; Yiye Zhao; Ye Ma; Xueqing Yao; Xuegang Sun
Journal: J Cell Commun Signal Date: 2018-01-24 Impact factor: 5.782

5. Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.

Authors: Douglas W Thomson; Daniel Poeckel; Nico Zinn; Christina Rau; Katrin Strohmer; Anne J Wagner; Alan P Graves; Jessica Perrin; Marcus Bantscheff; Birgit Duempelfeld; Viera Kasparcova; Joshi M Ramanjulu; G Scott Pesiridis; Marcel Muelbaier; Giovanna Bergamini
Journal: ACS Med Chem Lett Date: 2019-03-11 Impact factor: 4.345

Review 6. Targeting TANK-binding kinase 1 (TBK1) in cancer.

Authors: Or-Yam Revach; Shuming Liu; Russell W Jenkins
Journal: Expert Opin Ther Targets Date: 2020-10-05 Impact factor: 6.902

7. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.

Authors: Yuchuan Jiang; Siliang Chen; Qiang Li; Junjie Liang; Weida Lin; Jinying Li; Zhilong Liu; Mingbo Wen; Mingrong Cao; Jian Hong
Journal: Front Immunol Date: 2021-02-18 Impact factor: 7.561

8. TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss.

Authors: Lianxin Hu; Haibiao Xie; Xijuan Liu; Frances Potjewyd; Lindsey I James; Emily M Wilkerson; Laura E Herring; Ling Xie; Xian Chen; Johnny Castillo Cabrera; Kai Hong; Chengheng Liao; Xianming Tan; Albert S Baldwin; Kan Gong; Qing Zhang
Journal: Cancer Discov Date: 2019-12-06 Impact factor: 38.272

9. The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.

Authors: Moritz Möller; Julia Wasel; Julia Schmetzer; Ulrike Weiß; Markus Meissner; Susanne Schiffmann; Andreas Weigert; Christine V Möser; Ellen Niederberger
Journal: Int J Mol Sci Date: 2020-07-02 Impact factor: 5.923

Review 10. The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications.

Authors: Wenting Guo; Tijs Vandoorne; Jolien Steyaert; Kim A Staats; Ludo Van Den Bosch
Journal: Brain Date: 2020-06-01 Impact factor: 13.501